Ceva Animal Health Strengthens Its Growth Strategy with New Investors, Including Mérieux Institute and ARCHIMED

05/04/2025

Ceva Animal Health (Ceva), the fifth-largest global player in animal health, has announced a strategic restructuring of its capital, positioning itself for accelerated growth. The company’s long-standing investors, as well as two new influential partners—Mérieux Institute and ARCHIMED—have committed to this new funding round, reflecting their trust in Ceva’s continued success in the evolving animal health landscape.

A Restructured Capital for Continued Growth

Ceva has secured renewed investment from its existing group of supporters, including both the “Friends of Ceva” network and major financial investors led by Temasek. This renewed backing signals confidence in Ceva’s ability to sustain its impressive growth trajectory.

The restructuring also underscores Ceva’s commitment to its independent ownership. Dr. Marc Prikazsky, Chairman and CEO, and the company’s management have strengthened their participation, maintaining the majority of the voting rights. This decision ensures that Ceva’s long-term strategic vision remains in the hands of its core leadership team while allowing for accelerated expansion.

Strategic New Partners: Mérieux Institute and ARCHIMED

As part of this restructuring, Ceva has welcomed two new powerful investors: Mérieux Institute and ARCHIMED. These new partnerships will help fuel the company’s innovative research initiatives and global expansion.

The Mérieux Institute, a renowned leader in the healthcare sector, has joined forces with the Bettencourt-Meyers family’s Téthys Invest to increase its stake in Ceva. The Mérieux Institute brings decades of expertise in global health, strengthening Ceva’s ability to address emerging health challenges. Additionally, ARCHIMED, a French investment fund specializing in healthcare, has become a significant partner. Led by veterinarian Dr. Denis Ribon, ARCHIMED focuses on supporting companies with strong international growth potential, making it an ideal fit for Ceva’s global ambitions.

Long-Term Support from Trusted Investors

Ceva’s successful funding round has also seen renewed investment from other trusted partners, ensuring the company remains on a strong financial footing. PSP Investments, a Canadian pension fund with a long history of backing Ceva, has increased its stake in the company. Other key participants include Sofiprotéol, Mitsui & Co., and several local investment funds.

Temasek, a global investment firm based in Singapore, continues to be a leading investor, alongside other financial players like EMZ and Sagard (France), HOPU Investments (Asia), and Continental Grain Company (USA). These investors are known for their long-term commitment and strategic insight, which aligns perfectly with Ceva’s mission to drive innovation and enhance animal health worldwide.

A Proven Growth Story

Ceva’s remarkable growth over the past two decades is a testament to its innovation and leadership in animal health. Since its inception in 1999, the company’s revenue has soared fourteenfold, reaching €1.77 billion in 2024. Ceva is a trailblazer in animal health, having been the first veterinary company to develop and commercialize a cutting-edge nucleotide vaccine and invest in gene therapy for companion animals.

Innovation remains at the core of Ceva’s strategy, with a strong emphasis on preventive medicine. The company continues to make strides in addressing critical global health issues, including emerging zoonotic diseases that affect both animals and humans. By driving advancements in veterinary care, Ceva plays a vital role in supporting global food security and safeguarding animal health.

Committed to Sustainability

In addition to its dedication to innovation, Ceva is equally committed to addressing global environmental challenges. The company is actively working to reduce its environmental footprint and promote biodiversity. As an advocate for sustainable practices, Ceva integrates eco-friendly solutions into its operations, helping ensure a better future for both animals and the planet.

“I am delighted to see that in this new round of financing, the management’s participation, supported by the ‘Friends of Ceva’, is being strengthened alongside our historic financial investors and new entrants. Ceva plays a major role in animal health, particularly in the fight against emerging diseases, sometimes zoonotic, and in the treatment of chronic diseases affecting our loyal four-legged companions. At Ceva, we are convinced that we must continue to create bridges between different health sectors to protect the health of ecosystems and humans as well as global food security,”said Dr. Marc Prikazsky, Chairman and CEO of Ceva Animal Health.

Looking to the Future

With the renewed backing of its investors, Ceva is poised to continue expanding its global reach and advancing its research capabilities. The company’s leadership team is dedicated to creating solutions that address not only the health of animals but also the interconnected health of humans, ecosystems, and the broader environment.

Ceva also extends its gratitude to its advisory team, including Lazard, Rothschild, Weil, and Callisto, for their invaluable support throughout the restructuring process.

About Ceva Animal Health

With a team of 7,000 employees, Ceva Animal Health operates in 47 countries and serves veterinarians, livestock professionals, and pet owners globally. As a leader in animal health, Ceva provides cutting-edge vaccines, diagnostics, and therapeutic products designed to improve the lives of animals. Committed to innovation and sustainable growth, Ceva continues to shape the future of animal health and wellness.

Ceva Animal Health’s bold capital restructuring and new partnerships position it for an exciting future. With its focus on innovation, sustainability, and global health, the company is well-equipped to meet the challenges of tomorrow while continuing to lead the way in animal health.